Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Gattermann

Showing results (121-130 of 158) with videos related to

Pageof 16
Sort By:
Haematologica|October 14, 2011
Therapy-related myeloid neoplasms following treatment with radioiodineThomas Schroeder, Andrea Kuendgen, Sabine Kayser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemiaPierre Fenaux, Ghulam J Mufti, Eva Hellström-Lindberg, et al.
Leukemia Research|February 24, 2005
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemiaMignon L Loh, Simone Martinelli, Viviana Cordeddu, et al.
Blood|August 10, 2010
Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic valueAlexander E Smith, Azim M Mohamedali, Austin Kulasekararaj, et al.
Genome Research|September 13, 2024
Long-read transcriptome sequencing of CLL and MDS patients uncovers molecular effects of <i>SF3B1</i> mutationsAlicja Pacholewska, Matthias Lienhard, Mirko Brüggemann, et al.
Blood|August 24, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceHagop M Kantarjian, Francis Giles, Norbert Gattermann, et al.
Medicine|May 20, 2016
γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative NeoplasmJan Görtzen, Lena M Hunka, Maria Vonnahme, et al.
The Lancet. Oncology|February 24, 2009
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyPierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg, et al.
Leukemia|March 12, 2021
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trialJerald P Radich, Andreas Hochhaus, Tamás Masszi, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2018
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom studyDavid M Ross, Tamas Masszi, María Teresa Gómez Casares, et al.
Pageof 16

Showing results (121-130 of 158) with videos related to

Sort By:
Pageof 16
Haematologica|October 14, 2011
Therapy-related myeloid neoplasms following treatment with radioiodineThomas Schroeder, Andrea Kuendgen, Sabine Kayser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemiaPierre Fenaux, Ghulam J Mufti, Eva Hellström-Lindberg, et al.
Leukemia Research|February 24, 2005
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemiaMignon L Loh, Simone Martinelli, Viviana Cordeddu, et al.
Blood|August 10, 2010
Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic valueAlexander E Smith, Azim M Mohamedali, Austin Kulasekararaj, et al.
Genome Research|September 13, 2024
Long-read transcriptome sequencing of CLL and MDS patients uncovers molecular effects of <i>SF3B1</i> mutationsAlicja Pacholewska, Matthias Lienhard, Mirko Brüggemann, et al.
Blood|August 24, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceHagop M Kantarjian, Francis Giles, Norbert Gattermann, et al.
Medicine|May 20, 2016
γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative NeoplasmJan Görtzen, Lena M Hunka, Maria Vonnahme, et al.
The Lancet. Oncology|February 24, 2009
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyPierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg, et al.
Leukemia|March 12, 2021
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trialJerald P Radich, Andreas Hochhaus, Tamás Masszi, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2018
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom studyDavid M Ross, Tamas Masszi, María Teresa Gómez Casares, et al.
Pageof 16